Special access opens for rare metabolic and obesity disorders
NCT ID NCT04710056
Summary
This program provides special access to an investigational drug called REGN4461 for patients with rare diseases where the body's leptin signaling is deficient. It is for conditions like lipodystrophy (abnormal fat distribution) and monogenic obesity (a genetic form of obesity). Access is granted on a case-by-case basis and depends on the patient's location and specific circumstances.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.